Cathay Health

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies

Vensana℠ is actively investing in development and commercial stage companies across the medtech sector, including medical devices, diagnostics and data science, drug delivery, digital health, life science tools, and tech-enabled services. WHAT PARTNERSHIP MEANS TO US Vensana℠ places the highest value on partnering with experienced, insightful, and bold management teams. We hope to invest where our capital and commitment amplifies their success.

Established in 2023, KP Rx is a 100% founder-owned investment firm specialising in private and early-stage public healthcare investments in Australia and New Zealand. Founded by Hashan De Silva and backed by Karst Peak Capital, the firm targets high-potential biotech, medical devices, diagnostics, and health tech companies at a pivotal inflection point of value creation. Our Focus Creating a portfolio of Australia’s most promising healthcare companies. Our focus is on companies at or after Series A, specifically biotech companies at Phase 2 or medical device companies at or after regulatory clearance. Small-molecule Drugs Biological Products Cell & Gene Therapies Medical Devices Diagnostic Technologies AI for Healthcare Healthcare Software / SaaS Data and Analytics

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

AGP is a fund management company spun out from EDBI, a state-owned fund in Singapore, with former senior employees as founders. The fund will continue to have close affiliation to EDBI providing unique opportunities for collaboration and investments. We are raising a dedicated healthcare fund (“AGP Healthcare Fund” or “AGPHC”) to build on our successes at EDBI and to capture new opportunities. Our partners have a credible reputation built on years of working together at EDBI and having strong domain expertise in healthcare, with extensive network and deep linkages to the Singapore, regional, and global biomedical and healthcare ecosystem. Our investment areas* include medtech & manufacturing, services & others, healthtech, and biotech & therapeutics. At AGP Healthcare Fund, we focus on investing in growth-stage companies (Series C to pre-IPO) (~75%) and venture-stage companies (Series A and B) (~25%). Our unique position in serving both SEA/Asia and global markets is driven by our belief that SEA is an emerging innovation hub with tremendous potential to build differentiated and valuable healthcare companies. We see opportunities for healthcare companies to capitalize on the Asian growth momentum by leveraging Singapore's position as a nexus between the East and the West. With our global insights and proven track record, we provide valuable guidance and advice to founders in expanding their businesses globally. Investment areasMedtech & Mfg, Services & Others: minimally invasive devices, medical equipment manufacturing & distribution, surgical robotics, diagnostics, healthcare services, new modalities CRDMOs, life science equipment & consumables, drug manufacturing & distribution Healthtech: remote patient monitoring, virtual care delivery, digital health platform, workflow automation, healthcare analytics, AI in healthcare imaging, digital therapeutics, chronic disease management Biotech & Therapeutics: cell & gene therapy, RNA therapeutics, AI drug discovery, targeted therapy & immunotherapy, gene editing tools & infrastructure, regenerative medicine & tissue engineering, and life science tools

Our goal is to optimize value creation across all stages of our investment journey; from clinical trials and FDA approvals, through market validation and product adoption, to successful entry into capital markets and strategic deals. Driving HealthTech from business plan to business success Our unique strategic ecosystem and team’s active engagement help portfolio companies realize their full potential and achieve large-scale success. By providing unparalleled access to invaluable resources in the form of: Clinical infrastructures KOLs Big data Domain experts Financial backing We help our companies gain an in-depth understanding of clinical workflows and procedures, to ensure product-market fit under challenging health economics, deliver better care for patients and create value to all stake holders. We invest in the right fit We invest in promising mid-to-late stage companies developing innovative platform technologies that will become the gold standard in a broad range of disciplines. The main areas of focus include: Medical devices Diagnostics Digital health Healthcare IT AI and ML We look for highly fundable companies with strong management, broad IP protection and a proven track record of execution, that are poised to benefit from the strategic synergies offered by the ALIVE ecosystem.